Dabigatran etexilate requires dose reduction in patients with moderate renal impairment (CrCl 30–50 mL/min) because:

• A Dabigatran undergoes hepatic CYP3A4 metabolism that is reduced in renal failure due to accumulated uremic inhibitors
• B Renal impairment reduces hepatic albumin synthesis, increasing free dabigatran fraction
• C Dabigatran is converted to active thrombin-inhibiting metabolites renally, and impaired conversion reduces efficacy requiring compensation
• D Dabigatran itself (not a prodrug) is eliminated predominantly by the kidneys (80% unchanged), so renal impairment causes drug accumulation and bleeding risk ✓

Explanation

Dabigatran etexilate is hydrolysed by plasma and hepatic esterases to the active form dabigatran (not by CYP enzymes). Dabigatran itself is approximately 80% excreted unchanged by the kidneys. In renal impairment, clearance is reduced proportionally, causing drug accumulation and dose-dependent bleeding. Among DOACs, dabigatran is most renally dependent; apixaban has the least renal elimination (~27%).

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.